CD47 and cancer: Recently, Nie et al. designed pH-responsive M1 exosome nanobioconjugates for cancer treatment in which dibenzocyclooctyne-modified antibodies against CD47 and SIRPα were conjugated with azide-modified M1 exosomes linked with pH-sensitive benzoic-imine bonds.